VivoSim Labs (NASDAQ:VIVS) Issues Earnings Results

VivoSim Labs (NASDAQ:VIVS) released its quarterly earnings data on Tuesday. The company reported ($2.21) earnings per share for the quarter, FiscalAI reports. VivoSim Labs had a negative return on equity of 15.51% and a negative net margin of 861.27%.The business had revenue of $0.04 million during the quarter.

VivoSim Labs Price Performance

NASDAQ VIVS traded up $0.03 during midday trading on Tuesday, hitting $0.83. 71,372 shares of the company traded hands, compared to its average volume of 817,618. VivoSim Labs has a 52 week low of $0.78 and a 52 week high of $5.30. The company’s 50-day simple moving average is $1.18 and its 200-day simple moving average is $1.62. The company has a market cap of $2.18 million, a PE ratio of -0.27 and a beta of 1.40.

Institutional Investors Weigh In On VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP bought a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, VivoSim Labs presently has a consensus rating of “Sell”.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.